Relmada Ebit Per Revenue vs Revenue Per Share Analysis

RLMD Stock

USD 0.37 0.05 11.90%

Relmada Therapeutics financial indicator trend analysis is much more than just breaking down Relmada Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Relmada Therapeutics is a good investment. Please check the relationship between Relmada Therapeutics Ebit Per Revenue and its Revenue Per Share accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relmada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.

Ebit Per Revenue vs Revenue Per Share

Ebit Per Revenue vs Revenue Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Relmada Therapeutics Ebit Per Revenue account and Revenue Per Share. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Relmada Therapeutics' Ebit Per Revenue and Revenue Per Share is 0.96. Overlapping area represents the amount of variation of Ebit Per Revenue that can explain the historical movement of Revenue Per Share in the same time period over historical financial statements of Relmada Therapeutics, assuming nothing else is changed. The correlation between historical values of Relmada Therapeutics' Ebit Per Revenue and Revenue Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit Per Revenue of Relmada Therapeutics are associated (or correlated) with its Revenue Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Revenue Per Share has no effect on the direction of Ebit Per Revenue i.e., Relmada Therapeutics' Ebit Per Revenue and Revenue Per Share go up and down completely randomly.

Correlation Coefficient

0.96

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Ebit Per Revenue

Revenue Per Share

The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.

Most indicators from Relmada Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Relmada Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relmada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.At present, Relmada Therapeutics' Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 25.77, whereas Sales General And Administrative To Revenue is forecasted to decline to 0.98.

	2021	2023	2024 (projected)
Total Operating Expenses	125.7M	103.7M	108.9M
Cost Of Revenue	1.3K	1.1K	1.1K

Total Operating Expenses Cost Of Revenue

Relmada Therapeutics fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Total Current Assets	Common Stock	Other Current Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Non Current Assets Total	Non Currrent Assets Other	Retained Earnings Total Equity	Capital Surpluse	Other Stockholder Equity	Property Plant And Equipment Gross
Total Assets		0.17	0.96	-0.34	-0.64	0.95	0.33	1.0	-0.17	0.69	0.84	0.86	0.88	0.16	1.0	0.27	-0.29	0.81	-0.21	0.67	-0.4	-0.41	-0.73	0.78	0.75	-0.11
Total Current Liabilities	0.17		-0.05	-0.69	0.06	0.07	0.69	0.18	0.64	-0.1	0.01	0.01	0.1	1.0	0.17	0.74	0.65	-0.11	-0.27	-0.23	-0.42	-0.32	0.25	-0.14	-0.07	0.1
Total Stockholder Equity	0.96	-0.05		-0.19	-0.64	0.93	0.18	0.96	-0.22	0.7	0.84	0.85	0.85	-0.07	0.96	0.08	-0.44	0.82	-0.15	0.71	-0.28	-0.31	-0.78	0.8	0.75	-0.1
Net Debt	-0.34	-0.69	-0.19		-0.17	-0.28	-1.0	-0.33	-0.37	0.21	-0.29	-0.4	-0.56	-0.68	-0.34	-0.48	-0.35	-0.05	0.09	0.19	0.16	0.11	-0.14	0.15	0.1	-0.2
Retained Earnings	-0.64	0.06	-0.64	-0.17		-0.51	0.19	-0.65	0.27	-0.98	-0.24	-0.68	-0.43	0.07	-0.64	-0.08	0.37	-0.85	0.19	-0.85	0.34	0.34	0.75	-0.91	-0.98	0.14
Accounts Payable	0.95	0.07	0.93	-0.28	-0.51		0.27	0.95	-0.22	0.59	0.92	0.79	0.82	0.05	0.95	0.11	-0.4	0.77	-0.14	0.66	-0.3	-0.36	-0.74	0.75	0.64	-0.14
Cash	0.33	0.69	0.18	-1.0	0.19	0.27		0.32	0.37	-0.24	0.3	0.39	0.55	0.68	0.33	0.46	0.34	0.04	-0.09	-0.21	-0.15	-0.09	0.16	-0.17	-0.12	0.2
Cash And Short Term Investments	1.0	0.18	0.96	-0.33	-0.65	0.95	0.32		-0.16	0.7	0.83	0.85	0.87	0.16	1.0	0.28	-0.28	0.81	-0.22	0.67	-0.41	-0.42	-0.73	0.78	0.75	-0.11
Common Stock Total Equity	-0.17	0.64	-0.22	-0.37	0.27	-0.22	0.37	-0.16		-0.3	-0.24	-0.26	-0.17	0.65	-0.17	0.62	0.59	-0.32	-0.1	-0.38	-0.29	-0.31	0.41	-0.36	-0.29	-0.11
Common Stock Shares Outstanding	0.69	-0.1	0.7	0.21	-0.98	0.59	-0.24	0.7	-0.3		0.33	0.66	0.44	-0.11	0.69	0.07	-0.39	0.88	-0.21	0.89	-0.38	-0.4	-0.81	0.95	0.99	-0.16
Non Current Liabilities Total	0.84	0.01	0.84	-0.29	-0.24	0.92	0.3	0.83	-0.24	0.33		0.64	0.79	0.01	0.84	-0.03	-0.41	0.57	-0.18	0.46	-0.21	-0.21	-0.61	0.53	0.38	-0.08
Inventory	0.86	0.01	0.85	-0.4	-0.68	0.79	0.39	0.85	-0.26	0.66	0.64		0.92	0.0	0.86	0.1	-0.34	0.83	-0.16	0.64	-0.28	-0.24	-0.64	0.73	0.77	-0.04
Other Current Assets	0.88	0.1	0.85	-0.56	-0.43	0.82	0.55	0.87	-0.17	0.44	0.79	0.92		0.09	0.88	0.19	-0.25	0.68	-0.15	0.45	-0.28	-0.25	-0.52	0.54	0.56	-0.11
Total Liab	0.16	1.0	-0.07	-0.68	0.07	0.05	0.68	0.16	0.65	-0.11	0.01	0.0	0.09		0.16	0.72	0.64	-0.12	-0.28	-0.24	-0.41	-0.31	0.27	-0.15	-0.08	0.09
Total Current Assets	1.0	0.17	0.96	-0.34	-0.64	0.95	0.33	1.0	-0.17	0.69	0.84	0.86	0.88	0.16		0.27	-0.28	0.81	-0.22	0.67	-0.4	-0.41	-0.73	0.78	0.75	-0.11
Common Stock	0.27	0.74	0.08	-0.48	-0.08	0.11	0.46	0.28	0.62	0.07	-0.03	0.1	0.19	0.72	0.27		0.69	0.03	-0.22	-0.13	-0.63	-0.68	0.16	-0.04	0.1	-0.24
Other Current Liab	-0.29	0.65	-0.44	-0.35	0.37	-0.4	0.34	-0.28	0.59	-0.39	-0.41	-0.34	-0.25	0.64	-0.28	0.69		-0.48	-0.25	-0.59	-0.43	-0.33	0.66	-0.51	-0.37	0.09
Net Tangible Assets	0.81	-0.11	0.82	-0.05	-0.85	0.77	0.04	0.81	-0.32	0.88	0.57	0.83	0.68	-0.12	0.81	0.03	-0.48		-0.25	0.95	-0.4	-0.48	-0.93	0.94	0.9	-0.18
Property Plant And Equipment Net	-0.21	-0.27	-0.15	0.09	0.19	-0.14	-0.09	-0.22	-0.1	-0.21	-0.18	-0.16	-0.15	-0.28	-0.22	-0.22	-0.25	-0.25		-0.15	0.81	0.47	0.2	-0.21	-0.21	-0.05
Current Deferred Revenue	0.67	-0.23	0.71	0.19	-0.85	0.66	-0.21	0.67	-0.38	0.89	0.46	0.64	0.45	-0.24	0.67	-0.13	-0.59	0.95	-0.15		-0.28	-0.42	-0.96	0.95	0.87	-0.2
Non Current Assets Total	-0.4	-0.42	-0.28	0.16	0.34	-0.3	-0.15	-0.41	-0.29	-0.38	-0.21	-0.28	-0.28	-0.41	-0.4	-0.63	-0.43	-0.4	0.81	-0.28		0.86	0.26	-0.34	-0.39	0.23
Non Currrent Assets Other	-0.41	-0.32	-0.31	0.11	0.34	-0.36	-0.09	-0.42	-0.31	-0.4	-0.21	-0.24	-0.25	-0.31	-0.41	-0.68	-0.33	-0.48	0.47	-0.42	0.86		0.38	-0.38	-0.39	0.42
Retained Earnings Total Equity	-0.73	0.25	-0.78	-0.14	0.75	-0.74	0.16	-0.73	0.41	-0.81	-0.61	-0.64	-0.52	0.27	-0.73	0.16	0.66	-0.93	0.2	-0.96	0.26	0.38		-0.91	-0.8	0.17
Capital Surpluse	0.78	-0.14	0.8	0.15	-0.91	0.75	-0.17	0.78	-0.36	0.95	0.53	0.73	0.54	-0.15	0.78	-0.04	-0.51	0.94	-0.21	0.95	-0.34	-0.38	-0.91		0.95	-0.16
Other Stockholder Equity	0.75	-0.07	0.75	0.1	-0.98	0.64	-0.12	0.75	-0.29	0.99	0.38	0.77	0.56	-0.08	0.75	0.1	-0.37	0.9	-0.21	0.87	-0.39	-0.39	-0.8	0.95		-0.15
Property Plant And Equipment Gross	-0.11	0.1	-0.1	-0.2	0.14	-0.14	0.2	-0.11	-0.11	-0.16	-0.08	-0.04	-0.11	0.09	-0.11	-0.24	0.09	-0.18	-0.05	-0.2	0.23	0.42	0.17	-0.16	-0.15

Click cells to compare fundamentals

Relmada Therapeutics Account Relationship Matchups

Relmada Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	10.2M	118.2M	223.3M	152.9M	97.6M	60.8M
Total Current Liabilities	2.6M	12.6M	15.1M	12.5M	12.2M	9.2M
Total Stockholder Equity	7.6M	105.6M	208.3M	140.4M	85.4M	43.3M
Net Debt	(8.9M)	(2.5M)	(44.4M)	(5.4M)	(4.1M)	(4.3M)
Retained Earnings	(111.7M)	(179.3M)	(305.1M)	(462.1M)	(560.9M)	(532.9M)
Accounts Payable	924.4K	8.3M	11.2M	5.3M	3.5M	3.0M
Cash	9.2M	2.5M	44.4M	5.4M	4.1M	3.9M
Cash And Short Term Investments	9.2M	117.1M	211.9M	148.3M	96.3M	58.5M
Common Stock Total Equity	39.0K	14.5K	16.3K	30.1K	27.1K	25.7K
Common Stock Shares Outstanding	6.3M	15.6M	17.6M	29.6M	30.1M	31.6M
Liabilities And Stockholders Equity	10.2M	118.2M	223.3M	152.9M	97.6M	61.0M
Non Current Liabilities Total	2.7M	1.3M	8.3M	11.2M	5.3M	0.0
Inventory	459K	903.2K	11.3M	4.0M	4.6M	4.9M
Other Current Assets	(55.0)	903.2K	11.3M	4.0M	1.2M	1.6M
Total Liab	2.6M	12.6M	15.1M	12.5M	12.2M	9.4M
Total Current Assets	10.0M	118.1M	223.3M	152.9M	97.5M	60.6M
Common Stock	9.7K	16.3K	27.7K	30.1K	27.1K	16.5K
Other Current Liab	(45.0)	4.3M	3.9M	7.2M	8.7M	7.4M
Net Tangible Assets	115.7M	105.6M	208.3M	140.4M	161.5M	169.6M
Non Current Assets Total	235.4K	112.6K	28.3K	34.9K	43.1K	41.0K
Capital Surpluse	88.8M	119.2M	235.5M	602.5M	692.9M	727.5M
Other Stockholder Equity	119.3M	284.9M	513.3M	602.5M	646.2M	678.5M
Property Plant And Equipment Gross	7.2K	5K	1.3K	16.7K	15.0K	14.3K
Property Plant Equipment	12.1K	7.2K	5.0K	1.3K	1.1K	1.1K
Other Assets	190.8K	111.4K	28.3K	34.9K	31.4K	29.8K
Net Receivables	308.9K	79.5K	86.4K	512.4K	589.3K	618.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Relmada Therapeutics is a strong investment it is important to analyze Relmada Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Relmada Therapeutics' future performance. For an informed investment choice regarding Relmada Stock, refer to the following important reports:

How To Invest In Relmada

Details

Is Relmada Stock a good investment?

Details

What is Relmada Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relmada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.

You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Relmada Therapeutics. If investors know Relmada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Relmada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.86)

Return On Assets

(0.59)

Return On Equity

(1.00)

The market value of Relmada Therapeutics is measured differently than its book value, which is the value of Relmada that is recorded on the company's balance sheet. Investors also form their own opinion of Relmada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Relmada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Relmada Therapeutics' market value can be influenced by many factors that don't directly affect Relmada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Relmada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Relmada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Relmada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Relmada Ebit Per Revenue vs Revenue Per Share Analysis

Ebit Per Revenue vs Revenue Per Share

Ebit Per Revenue vs Revenue Per Share Correlation Analysis

Correlation Coefficient

Ebit Per Revenue

Revenue Per Share

Relmada Therapeutics fundamental ratios Correlations

Relmada Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Relmada Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Stockholder Equity	+ 0.99	Common Stock Shares Outstanding
Total Stockholder Equity	+ 0.96	Total Assets

Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.98	Retained Earnings
Common Stock Shares Outstanding	- 0.98	Retained Earnings
Retained Earnings Total Equity	- 0.96	Current Deferred Revenue
Retained Earnings Total Equity	- 0.93	Net Tangible Assets
Capital Surpluse	- 0.91	Retained Earnings Total Equity